Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 116 800 KRW -1.1% Market Closed
Market Cap: 8.6T KRW
Have any thoughts about
Yuhan Corp?
Write Note

Yuhan Corp
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Yuhan Corp
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Yuhan Corp
KRX:000100
Pre-Tax Income
â‚©169.6B
CAGR 3-Years
8%
CAGR 5-Years
21%
CAGR 10-Years
4%
SK Biopharmaceuticals Co Ltd
KRX:326030
Pre-Tax Income
-â‚©43.9B
CAGR 3-Years
43%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Pre-Tax Income
â‚©121.7B
CAGR 3-Years
26%
CAGR 5-Years
44%
CAGR 10-Years
18%
Hanmi Pharm Co Ltd
KRX:128940
Pre-Tax Income
â‚©226.1B
CAGR 3-Years
29%
CAGR 5-Years
30%
CAGR 10-Years
21%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Pre-Tax Income
â‚©11.9B
CAGR 3-Years
N/A
CAGR 5-Years
-9%
CAGR 10-Years
-2%
C
Celltrion Pharm Inc
KOSDAQ:068760
Pre-Tax Income
â‚©22.4B
CAGR 3-Years
-19%
CAGR 5-Years
39%
CAGR 10-Years
18%
No Stocks Found

Yuhan Corp
Glance View

Market Cap
8.6T KRW
Industry
Pharmaceuticals

In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.

Intrinsic Value
55 502.27 KRW
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Yuhan Corp's Pre-Tax Income?
Pre-Tax Income
169.6B KRW

Based on the financial report for Sep 30, 2024, Yuhan Corp's Pre-Tax Income amounts to 169.6B KRW.

What is Yuhan Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
4%

Over the last year, the Pre-Tax Income growth was 141%. The average annual Pre-Tax Income growth rates for Yuhan Corp have been 8% over the past three years , 21% over the past five years , and 4% over the past ten years .

Back to Top